Manfred Welslau

8.1k total citations · 3 hit papers
79 papers, 5.4k citations indexed

About

Manfred Welslau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Manfred Welslau has authored 79 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Manfred Welslau's work include HER2/EGFR in Cancer Research (17 papers), Advanced Breast Cancer Therapies (16 papers) and Lymphoma Diagnosis and Treatment (15 papers). Manfred Welslau is often cited by papers focused on HER2/EGFR in Cancer Research (17 papers), Advanced Breast Cancer Therapies (16 papers) and Lymphoma Diagnosis and Treatment (15 papers). Manfred Welslau collaborates with scholars based in Germany, United States and Switzerland. Manfred Welslau's co-authors include Véronique Dièras, David Miles, Ian E. Krop, Mark D. Pegram, Luca Gianni, Sunil Verma, Ellie Guardino, Kim T. Blackwell, Fang Ting Liang and Steven R. Olsen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Manfred Welslau

70 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

2012 2.7k citations Sunil Verma, David Miles et al. New England Journal of Medicine profile →
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

2013 962 citations Mathias Rummel, N. Niederle et al. The Lancet profile →
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

2017 465 citations Véronique Dièras, David Miles et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Manfred Welslau

Since Specialization

Citations

This map shows the geographic impact of Manfred Welslau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manfred Welslau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manfred Welslau more than expected).

Fields of papers citing papers by Manfred Welslau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manfred Welslau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manfred Welslau. The network helps show where Manfred Welslau may publish in the future.

Co-authorship network of co-authors of Manfred Welslau

This figure shows the co-authorship network connecting the top 25 collaborators of Manfred Welslau. A scholar is included among the top collaborators of Manfred Welslau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manfred Welslau. Manfred Welslau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First‐linenab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Final results of the NEPTUN study 2023 ·International Journal of Cancer ·Tobias Dechow, Jorge Riera‐Knorrenschild, Björn Hackanson, Jan Janßen, Holger Schulz, (unknown), Marco Chiabudini, Ludwig Fischer von Weikersthal, Stephan Budweiser, (unknown), (unknown), Manfred Welslau, Karin Potthoff	2
2	Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study 2022 ·Journal of bone oncology ·Andreas Jakob, (unknown), Arnd Nusch, (unknown), Roland Schnell, (unknown), (unknown), (unknown), Christoph Losem, Manfred Welslau, (unknown), Karin Potthoff	7
3	Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer 2022 ·ESMO Open ·Natansh D. Modi, (unknown), (unknown), Ahmad Y. Abuhelwa, (unknown), (unknown), Ross A. McKinnon, (unknown), (unknown), Sandra M. Swain, Manfred Welslau, Michael J. Sorich, Ashley M. Hopkins	10
4	A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer 2021 ·Cancers ·Markus Hecht, D Hahn, (unknown), Matthias Hautmann, Dietmar Reichert, (unknown), Claus Belka, Tobias Bergmann, Thomas Göhler, Manfred Welslau, Christina Große-Thie, Orlando Guntinas‐Lichius, Jens von der Grün, Panagiotis Balermpas, (unknown), Diethelm Messinger, (unknown), Rainer Fietkau	5
5	924P HANNA: Effectiveness and quality-of-life data from a real-world study of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab in Germany 2021 ·Annals of Oncology ·(unknown), (unknown), D Hahn, (unknown), Boris Kubuschok, Ulrike Bockmühl, Günther Klautke, (unknown), (unknown), Dirk Beutner, Jens Büntzel, Jens von der Grün, Chia‐Jung Busch, Bálint Tamaskovics, Jorge Riera‐Knorrenschild, (unknown), Manfred Welslau, Thomas Gauler, (unknown), Andreas Dietz	0
6	P-58 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING CRC 2021 ·Annals of Oncology ·Sebastian Stintzing, G Hübner, Jörg Schröder, Jens Kisro, Manfred Welslau, (unknown), Thomas Göhler, (unknown), (unknown), (unknown), (unknown), (unknown), Dirk Arnold, Armin Gerger, Susanna Hegewisch‐Becker, Arndt Vogel, Thomas Winder, Gerald W. Prager	0
7	Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer 2020 ·BMC Cancer ·Markus Hecht, D Hahn, (unknown), Matthias Hautmann, Dietmar Reichert, (unknown), Claus Belka, Tobias Bergmann, Thomas Göhler, Manfred Welslau, Christina Große-Thie, Orlando Guntinas‐Lichius, Jens von der Grün, Panagiotis Balermpas, (unknown), Diethelm Messinger, (unknown), Rainer Fietkau	9
8	1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma 2020 ·Annals of Oncology ·S-E. Al-Batran, (unknown), Thomas J. Ettrich, K Borchert, A. Kretzschmar, Christian Teschendorf, Gabriele Margareta Siegler, (unknown), Eray Goekkurt, Manfred Welslau, Rolf Mahlberg, Nils Homann, Daniel Pink, Wolf O. Bechstein, Peter Reichardt, Timo Gaiser, Disorn Sookthai, Claudia Pauligk, Thorsten Oliver Goetze, Ralf‐Dieter Hofheinz	15
9	PCN508 A COMPARISON OF PATIENT CHARACTERISTICS TREATED WITH NIVOLUMAB FOR RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN GERMANY AND THE USA 2019 ·Value in Health ·(unknown), Manfred Welslau, Thomas Gauler, Kieran Rothnie, (unknown), Andreas Dietz	1
10	Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial 2017 ·Supportive Care in Cancer ·(unknown), Bernd Weiß, Uirassu Borges, (unknown), Robert Dengler, (unknown), Manfred Welslau, (unknown)	24
11	Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape 2017 ·Annals of Oncology ·Jens Bedke, Manfred Welslau, Martin Boegemann, Martin Schostak, (unknown), (unknown), Thomas Wolf, Jan Schleicher, Christian Doehn, Carsten Grüllich, Viktor Grünwald, Thomas Steiner, Rainer Ehneß, (unknown), (unknown), Peter J. Goebell	1
12	The PAZOREAL non-interventional study to assess efficacy and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma (mRCC) treatment landscape 2016 ·Annals of Oncology ·(unknown), Christian Doehn, Carsten Grüllich, Viktor Grünwald, Thomas Steiner, Rainer Ehneß, Manfred Welslau	2
13	Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial 2015 ·The Lancet Oncology ·Mathias Rummel, Ulrich Kaiser, Christina Balser, Martina Stauch, Wolfram Brugger, Manfred Welslau, N. Niederle, Christoph Losem, (unknown), Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, (unknown), (unknown), Frank Kauff, Wolfgang Blau, Axel Hinke, Juergen Barth	110
14	Trastuzumab in advanced breast cancer – a decade of experience in Germany 2014 ·BMC Cancer ·Christian Jackisch, Winfried Schoenegg, Dietmar Reichert, Manfred Welslau, (unknown), (unknown), Hans Tesch, (unknown), (unknown), Axel Hinke	13
15	Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival – Results from a prospective, observational study in Germany 2014 ·The Breast ·Christian Jackisch, Manfred Welslau, Winfried Schoenegg, (unknown), (unknown), (unknown), Marcus Schmidt, Thomas Göhler, (unknown), (unknown), Axel Hinke	15
16	Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA 2014 ·Annals of Oncology ·Ian E. Krop, Nancy U. Lin, Kimberly Blackwell, Ellie Guardino, Jens Huober, Mengdi Lu, David Miles, Meghna Samant, Manfred Welslau, Véronique Dièras	286
17	Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer 2013 ·Cancer ·Manfred Welslau, Véronique Dièras, Joohyuk Sohn, Sara A. Hurvitz, Deepa Lalla, Fang Ting Liang, Betsy Althaus, Ellie Guardino, David Miles	90
18	Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial breakdown → 2013 ·The Lancet ·Mathias Rummel, N. Niederle, Georg Maschmeyer, Gamal-Andre Banat, Ulrich von Grünhagen, Christoph Losem, Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz Dürk, Harald Balló, Martina Stauch, Fritz Roller, Juergen Barth, Dieter Hoelzer, Axel Hinke, Wolfram Brugger	962
19	Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer breakdown → 2012 ·New England Journal of Medicine ·Sunil Verma, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark D. Pegram, Do‐Youn Oh, Véronique Dièras, Ellie Guardino, Fang Ting Liang, Michael W. Lu, Steven R. Olsen, Kim T. Blackwell	2665
20	Transferrin Derivatives with Growth Factor Activities in Acute Myeloblastic Leukemia:An Autocrine/Paracrine Pathway 1990 ·Hämatologie und Bluttransfusion ·Karl-Heinz Pflüger, (unknown), Manfred Welslau, H. Köppler, K. Havemann	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact